Foghorn Therapeutics

Q2 FY2026 EarningsQ2 FY2026 significantly outperformed consensus with revenue of $16.1M vs. $7.9M expected, driven by a $14.2M catch-up adjustment in the Lilly collaboration. GAAP EPS of -$0.10 beat the -$0.25 consensus by $0.15, supported by both the revenue surge and a 15% reduction in R&D spending. With a cash balance of $167.6M, the company extended its runway into H1 2028, though the CBPd-171 program faces operational delays.